Issue 46 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

9

No.

46

December 02, 1983Dec 02, 1983

Free

DOWNLOAD THE PDF

Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now

Cooperative Group Chairman Unhappy Over Exclusion From Funding at Recommended Levels

Workshop Calls For Improved Surgical Oncology Training Programs

Recent Issues

Volume 51 | Issue 18 - May 09, 2025

Volume 51 | Issue 17 - May 02, 2025

Volume 51 | Issue 16 - April 25, 2025

Volume 51 | Issue 15 - April 18, 2025

Volume 51 | Issue 14 - April 11, 2025

Volume 51 | Issue 13 - April 04, 2025